This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

October 26-28, 2021
2:30pm - 5:00pm CETOnline Training Course

Below is What Will Be Covered:

The course will be 2.5 each day. In addition to the content below there will be (1) break per day as well as time for Q&A and group discussion. 

October 26-28, 2021:
8:30am - 11:00am EST / 5:30am - 7:00pm PST / 1:30pm - 4:00pm GMT / 2:30pm - 5:00pm CET

Introduction to Speaker and Workshop 

  • Welcome words
  • Speaker introduction
  • Content of the Workshop
  • What is a conjugate?

Introduction to Therapeutic Oligonucleotide Conjugates I 

  • Different types of oligonucleotides and their mode of action.
  • Why do we need Oligonucleotide conjugates?
  • Do we always need Oligonucleotide conjugates?
  • Clinical status of Oligonucleotide conjugates

Introduction to Therapeutic Oligonucleotide Conjugates II

  • Disease Areas of interest
  • Ligand opportunities
  • Lipid, Antibody, GalNAc siRNA conjugates
  • Lipid, Antibody, GalNac ASO conjugates
  • Peptide ASO, SSO conjugates
  • Antibody SSO conjugates
  • Two choices in Oligonucleotide conjugate synthesis

Oligonucleotide Conjugate Synthesis

  • Solid phase synthesis of conjugates
  • Solution phase synthesis of conjugates